Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 1, 2006 (Three and Nine Months)
Business Overview: Illumina develops, manufactures, and markets tools for the large-scale analysis of genetic variation and biological function, including genotyping and gene expression systems (BeadArray technology), oligonucleotides, and related services. The company operates in a single segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 1, 2006 | 9 Months Ended Oct 1, 2006 | 9 Months Ended Oct 2, 2005 |
|---|---|---|---|
| Total Revenue | $53,472 | $124,151 | $50,488 |
| Net Income (Loss) | $16,162 | $22,826 | $(21,200) |
| Net Income (Loss) Per Share (Diluted) | $0.32 | $0.48 | $(0.53) |
| Operating Cash Flow | N/A | $30,219 | $(11,088) |
| Cash & Short-Term Investments | $169,942 | $169,942 | N/A |
| Total Debt | $94 | $94 | $172 |
Margins (Nine Months Ended Oct 1, 2006):
- Gross Margin on Product Revenue: 68%
- Gross Margin on Service Revenue: 69%
- Operating Margin: 17%
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 174% year-over-year for the quarter and 146% for the nine-month period. Product revenue grew 188% (quarter) and 159% (nine months), driven by higher consumable sales (HumanHap300 and HumanHap550 BeadChips) and a doubling of the installed base of BeadArray Readers.
- Profitability Turnaround: The company reported a net income of $16.2 million for the quarter and $22.8 million for the nine months, compared to a net loss of $1.4 million and $21.2 million in the prior year periods. This shift is attributed to significant revenue growth and the absence of the $15.8 million in-process research and development (IPR&D) charge recorded in the prior year related to the CyVera acquisition.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased 91% (quarter) and 96% (nine months). This was driven by stock-based compensation (due to SFAS No. 123R adoption) and increased legal costs related to the Affymetrix litigation.
- Stock-Based Compensation: Adoption of SFAS No. 123R resulted in an incremental $10.2 million expense for the nine months ended October 1, 2006, reducing net income per diluted share by $0.21.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects continued growth in product revenue due to new product launches (HumanHap650Y, iSelect) and an expanding installed base. However, they anticipate continued substantial costs for R&D and SG&A to support commercialization and infrastructure expansion.
- Liquidity: As of October 1, 2006, the company held $169.9 million in cash, cash equivalents, and short-term investments. Management believes current resources are sufficient to fund operations for the foreseeable future, though future capital needs depend on litigation outcomes and market acceptance.
- Legal Proceedings (Material Risk):
- Affymetrix Litigation: Affymetrix alleges patent infringement regarding BeadArray products. Trial was rescheduled to March 5, 2007. An unfavorable outcome could result in injunctions or significant damages.
- Dr. Anthony Czarnik: A former employee alleges inventorship correction and fraud. The court dismissed some counts, but the case remains pending.
- Unusual Items:
- Genizon Investment: Illumina purchased a $3.0 million secured convertible debenture in Genizon BioSciences. Approximately $3.0 million of revenue related to product shipments to Genizon has been deferred as a long-term liability due to "linked" transaction accounting rules.
- deCODE Collaboration: Approximately $2.0 million of revenue and $1.3 million of costs related to instrumentation and product shipments to deCODE genetics have been deferred.
Key Facts for Investor Verification
- Revenue Recognition Timing: Verify the impact of deferred revenue related to the Genizon and deCODE collaborations on future earnings recognition.
- Legal Exposure: Monitor the status of the Affymetrix patent litigation, as an adverse ruling could materially impact the ability to sell core products.
- Stock-Based Compensation Impact: Assess the ongoing impact of SFAS No. 123R on future operating margins, with approximately $46.7 million of unrecognized compensation cost remaining.
- Product Mix Sustainability: Confirm if the high gross margins (68-69%) are sustainable given the company's expectation of increasing price competition in the genotyping market.
- Manufacturing Capacity: Verify that the tenfold increase in manufacturing capacity for BeadChips is sufficient to meet demand without quality issues or yield reductions.